On June 1, 2017, The Medicines Company (the “Company”) commenced implementation of a workforce reduction in connection with the Company’s voluntary discontinuation and market withdrawal of IONSYS in the United States and the cessation of related commercialization activities, effective June 19, 2017, with the New Drug Application for IONSYS remaining open to December 31, 2017. The voluntary discontinuation and withdrawal from the market of IONSYS is not due to any safety or product quality concerns.

The workforce reduction will result in the Company reducing its personnel by approximately 60 employees, representing approximately 15% of the Company’s workforce. The Company expects to record a pre-tax charge of approximately $270 million to $280 million associated with the discontinuation and market withdrawal of IONSYS in the United States market, of which approximately $270 million is expected to relate to non-cash impairment charges (including inventory obsolescence charges) and up to $10 million is expected to relate to cash severance and other employee costs. The Company expects the charges will be recognized in the second quarter of 2017. The Company expects to realize estimated annualized cost savings from the voluntary discontinuation and market withdrawal of IONSYS of approximately $35 million.

Safe Harbor

Statements contained in this Current Report on Form 8-K about The Medicines Company, the voluntary discontinuation and market withdrawal of IONSYS in the United States market, expected charges and cost savings, and all other statements contained herein that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “believes,” “anticipates,” “estimates” and “expects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include such factors as are set forth in the risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission, including, without limitation, the risk factors detailed in the Company’s Quarterly Report on Form 10-Q filed on May 5, 2017, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.